Evidence map›Paper›PMID 41778249›Full record

ArticleCancer diagnosis & prognosis

Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.

Nobuki Furubayashi, Jiro Tsujita, Azusa Takayama, Yuta Shiraishi, Motonobu Nakamura, Takahito Negishi

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nobuki FurubayashiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Jiro TsujitaDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Azusa TakayamaDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yuta ShiraishiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Motonobu NakamuraDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Takahito NegishiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: This study aimed to describe the selection of first-line treatment and early outcomes in patients with Patients and Methods: We retrospectively investigated 46 patients with Results: The median patient age was 73 years, and most patients had LATITUDE high-risk disease and CHAARTED high-volume disease. Patients in the monotherapy group were significantly older than those in the doublet group and triplet group (80 Conclusion: In Japan, treatment intensity in patients with

Indexed as

androgen deprivation therapydocetaxeldoublet therapyJapanMetastatic castration-sensitive prostate cancershared decision-makingtriplet therapy

Identifiers

PMID41778249
PMCPMC12951386

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.